





10 - 15 - 01

A
Box 901jc872 U.S. PRO
09/976605

10/11/01

Certificate of Mailing	
Date of Deposit <u>October 11, 2001</u>	Label Number: <u>EL 834597981 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Guy Beardsley</u> Printed name of person mailing correspondence	<u>Guy Beardsley</u> Signature of person mailing correspondence

UTILITY PATENT APPLICATION TRANSMITTAL UNDER 37 C.F.R. § 1.53(b)	
Attorney Docket Number	50082/015002
Applicant	Grant McFadden and Karim Essani
Title	NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNE MODULATION
PRIORITY INFORMATION:	
This application claims the benefit of the filing date of United States provisional patent application 60/239,354, filed October 11, 2000.	
SMALL ENTITY STATUS:	
<input checked="" type="checkbox"/> Applicant claims small entity status under 37 C.F.R. § 1.27.	
APPLICATION ELEMENTS:	
Cover sheet	[1] pages
Specification	[52] pages
Claims	[10] pages
Abstract	[1] pages
Drawing (Figs. 1-9)	[9] sheets
Combined Declaration and POA, which is: <input checked="" type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input type="checkbox"/> A copy from prior application [**SERIAL NUMBER**] and the entire disclosure of the prior application is considered as being part of the disclosure of this new application and is hereby incorporated by reference therein.	[2] pages
Sequence Statement	[2] pages
Sequence Listing on Paper	[6] pages
Sequence Listing on Diskette	[1] disk
Preliminary Amendment	[**] pages
IDS	[**] pages

Form PTO 1449	[**] pages
Cited References	[**] references
Recordation Form Cover Sheet and Assignment	[**] pages
English Translation	[**] pages
Certified Copy of Priority Document	[**] pages
Return Receipt Postcard	1
FILING FEES:	
Basic Filing Fee: \$370	\$370.00
Excess Claims Fee: $78 - 20 = 58 \times \$9$	\$522.00
Excess Independent Claims Fee: $22 - 3 = 19 \times \$42$	\$798.00
Multiple Dependent Claims Fee: \$140	\$140.00
Total Fees:	\$1,830.00
<input checked="" type="checkbox"/> Enclosed is a check for \$1,830.00 to cover the total fees. <input type="checkbox"/> Charge [**AMOUNT**] to Deposit Account No. 03-2095 to cover the total fees. <input type="checkbox"/> The filing fee is not being paid at this time. <input checked="" type="checkbox"/> Please apply any other charges, or any credits, to Deposit Account No. 03-2095.	
CORRESPONDENCE ADDRESS:	
Kristina Bieker-Brady, Ph.D. Reg. No. 39,109 Clark & Elbing LLP 176 Federal Street Boston, MA 02110	Telephone: 617-428-0200 Facsimile: 617-428-7045
CUSTOMER NO: 21559	
 Signature	 Date

F:\50082\50082.015002 Utility Transmittal.wpd



21559

PATENT TRADEMARK OFFICE

PATENT
ATTORNEY DOCKET NO. 50082/015002

Certificate of Mailing: Date of Deposit: October 11, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **Express Mail Post Office to Addressee** with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.

Guy Beardsley
Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Grant McFadden et al.	Art Unit:	Not Assigned Yet
Serial No.:	Not Assigned Yet	Examiner:	Not Assigned Yet
Filed:	October 11, 2001	Customer No.:	21559
Title:	NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNE MODULATION		

Assistant Commissioner For Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of six pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout

the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.


As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,



Krishna Breker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE